Can blood tests predict severe diarrhea from breast cancer drug?
NCT ID NCT07490509
First seen Jun 24, 2026 · Last updated Jul 22, 2026 · Updated 3 times
Summary
This study will enroll 235 women with hormone receptor-positive, HER2-negative breast cancer who are taking abemaciclib after surgery. Researchers want to see if higher levels of the drug in the blood are linked to severe diarrhea, a common side effect. By understanding this link, doctors may one day adjust doses to reduce side effects while keeping the drug effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- abemaciclib
- What this could lead to
- If successful, this could lead to personalized dosing of abemaciclib to reduce severe diarrhea while maintaining its cancer-fighting benefits.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find a clear link between drug levels and side effects, and any dosing adjustments would need further testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABEMACICLIB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?